Beckman Coulter
This article was originally published in The Gray Sheet
Executive Summary
Firm acquires full rights for Nephromics' preeclampsia assay development program, currently in clinical testing for use with Beckman Coulter's UniCel Dxl and Access immunoassay systems and UniCel DxCi chemistry-immunoassay work cells. In 2005, the companies inked a licensing agreement giving Beckman Coulter non-exclusive access to the program. Deal also includes rights to acquire Nephromics' worldwide diagnostic assets. According to Beckman Coulter, there are no specific in vitro diagnostic tests for preeclampsia, a hypertensive disorder that occurs in up to 10% of pregnancies. The firm says it hopes to launch the tests in 2009